Literature DB >> 19025946

Head-to-head comparison between delayed enhancement and percent infarct mapping for assessment of myocardial infarct size in a canine model.

Balázs Ruzsics1, Pál Surányi, Pál Kiss, Brigitta C Brott, Ada Elgavish, Tamas Simor, Gabriel A Elgavish.   

Abstract

PURPOSE: To compare a novel method, percent-infarct-mapping (PIM), with conventional delayed enhancement (DE) of contrast for accurate myocardial viability assessment. Contrary to signal intensity (SI), the longitudinal relaxation-rate enhancement (DeltaR1) is an intrinsic parameter linearly proportional to the concentration of contrast agent (CA). Determining DeltaR1 voxel-by-voxel, after administering an infarct-avid CA, allows determination of per-voxel percentage of infarcted tissue. The feasibility of generating PIM is demonstrated in canine reperfused infarction using an infarct-avid, persistent-CA (PCA), (Gd)(ABE-DTTA). PIM is compared to the DE method using Gd(DTPA), and both to triphenyltetrazolium chloride (TTC) staining histochemistry.
MATERIALS AND METHODS: In six dogs, 48 hours following closed-chest, 180-minute coronary occlusion, DE imaging was carried out. PCA was administered immediately thereafter. Pixel-by-pixel R1 maps of the entire left ventricle (LV) were generated 48 hours after PCA using inversion-recovery with multiple inversion times. R1, DeltaR1, and percent-infarct values were calculated voxel-by-voxel.
RESULTS: Significant correlations (P < 0.01, R >or= 0.8) were obtained for percent-infarct-per-slice (PIS) determined by DE or PIM vs. those from corresponding TTC-stained slices. Compared to TTC, DE overestimated PIS by 32 +/- 18%. PIM underestimated PIS by 2.5 +/- 4.9%. Infarction fraction overestimation was 29 +/- 6% of LV by DE, but only 1.0 +/- 2.3% by PIM. Errors with PIM were significantly smaller than those with DE. Infarct area determined by signal intensity was similarly overestimated whether using Gd(DTPA) or Gd(ABE-DTTA).
CONCLUSION: The DeltaR1-based PIM method is highly reproducible and more accurate than DE for quantifying myocardial viability in vivo. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19025946     DOI: 10.1002/jmri.21571

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  5 in total

1.  The histogram analysis of diffusion-weighted intravoxel incoherent motion (IVIM) imaging for differentiating the gleason grade of prostate cancer.

Authors:  Yu-Dong Zhang; Qing Wang; Chen-Jiang Wu; Xiao-Ning Wang; Jing Zhang; Hui Liu; Xi-Sheng Liu; Hai-Bin Shi
Journal:  Eur Radiol       Date:  2014-11-28       Impact factor: 5.315

2.  Percent infarct mapping for delayed contrast enhancement magnetic resonance imaging to quantify myocardial viability by Gd(DTPA).

Authors:  Tamás Simor; Pál Surányi; Balázs Ruzsics; Attila Tóth; Levente Tóth; Pál Kiss; Brigitta C Brott; Akos Varga-Szemes; Ada Elgavish; Gabriel A Elgavish
Journal:  J Magn Reson Imaging       Date:  2010-10       Impact factor: 4.813

3.  Acute infarct selective MRI contrast agent.

Authors:  Robert Kirschner; Akos Varga-Szemes; Tamas Simor; Pal Suranyi; Pal Kiss; Balazs Ruzsics; Brigitta C Brott; Ada Elgavish; Gabriel A Elgavish
Journal:  Int J Cardiovasc Imaging       Date:  2011-02-19       Impact factor: 2.357

4.  Differentiation of acute and four-week old myocardial infarct with Gd(ABE-DTTA)-enhanced CMR.

Authors:  Robert Kirschner; Levente Toth; Akos Varga-Szemes; Tamas Simor; Pal Suranyi; Pal Kiss; Balazs Ruzsics; Attila Toth; Robert Baker; Brigitta C Brott; Silvio Litovsky; Ada Elgavish; Gabriel A Elgavish
Journal:  J Cardiovasc Magn Reson       Date:  2010-04-07       Impact factor: 5.364

5.  Myocardial tissue characterization by combining late gadolinium enhancement imaging and percent edema mapping: a novel T2 map-based MRI method in canine myocardial infarction.

Authors:  Pal Suranyi; Gabriel A Elgavish; U Joseph Schoepf; Balazs Ruzsics; Pal Kiss; Marly van Assen; Brian E Jacobs; Brigitta C Brott; Ada Elgavish; Akos Varga-Szemes
Journal:  Eur Radiol Exp       Date:  2018-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.